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The PIK3C3 locus was implicated in case-case genome-wide association study of systemic lupus erythematosus (SLE) which we
had performed to detect genes associated with autoantibodies and serum interferon-alpha (IFN-α). Herein, we examine a PIK3C3
promoter variant (rs3813065/-442 C/T) in an independent multiancestral cohort of 478 SLE cases and 522 controls. rs3813065
C was strongly associated with the simultaneous presence of both anti-Ro and anti-Sm antibodies in African-American patients
[OR = 2.24 (1.34–3.73), P = 2.0 × 10
−3]. This autoantibody proﬁle was associated with higher serum IFN-α (P = 7.6 × 10
−6). In
the HapMap Yoruba population, rs3813065 was associated with diﬀerential expression of ERAP2 (P = 2.0 ×10
−5), which encodes
an enzyme involved in MHC class I peptide processing. Thus, rs3813065 C is associated with a particular autoantibody proﬁle
and altered expression of an MHC peptide processing enzyme, suggesting that this variant modulates serologic autoimmunity in
African-American SLE patients.
1.Introduction
Systemic lupus erythematosus (SLE) is a systemic autoim-
mune disorder characterized by involvement of multiple
organ systems including the skin, musculoskeletal, renal, and
hematologicsystems.Whiletheexactpathogenicmechanism
of SLE is unknown, strong evidence exists for contributions
from both genetic risk factors and environmental events
which lead to an irreversible break in immunologic self-
tolerance [1]. SLE is a devastating disease, typically aﬀecting
young women during the reproductive years, resulting in
signiﬁcant morbidity and mortality [2]. SLE is nine times
more common in women than in men [3], and four times
more common in people of African-American ancestry than
those of European-American ancestry [1].
Interferon-alpha (IFN-α) is a pleiotropic type I inter-
feron which can bridge the innate and adaptive immune
systemsandthusmaysetthresholdsforself-tolerance.Serum
IFN-α is elevated in many SLE patients [4]. Recombinant
human IFN-α administered as a therapy for chronic viral
hepatitis and malignancy is thought to cause SLE in some
patients [5]. IFN-α-induced SLE typically resolves after the
IFN-α is discontinued [6, 7], supporting the idea that IFN-
α was causal. Serum IFN-α is also abnormally high in 20%
of healthy ﬁrst-degree relatives of SLE patients, and strong
familial aggregation of high serum IFN-α has been observed
in lupus families, supporting heritability of this trait [8]. The
high IFN-α trait in SLE families is inherited in a complex
fashion, suggesting polygenic inheritance which is not fully
characterized currently [8–11].
Autoantibodies directed at double-stranded DNA
(dsDNA) and RNA-binding proteins (anti-Ro, anti-La,
anti-Sm, and anti-RNP, collectively anti-RBP) are character-
istically found in SLE sera and are the strongest known
predictors of high serum IFN-α in SLE patients [8]. Immune
complexes formed by these autoantibodies can directly2 Journal of Biomedicine and Biotechnology
stimulateIFN-αproductioninvitro,likelyviatheendosomal
Toll-like receptors [12]. These data suggest that these SLE-
associated autoantibodies are correlated with and likely
mechanistically related to serum IFN-α. SLE-associated
autoantibodies are also a heritable trait in SLE families [13],
andanumberofestablishedSLE-risklocihavedemonstrated
associations with autoantibodies [14–16].
We have recently conducted a case-case genome-wide
association study (GWAS) to determine the genetic factors
associated with SLE- associated autoantibodies and high
serum IFN-α (Kariuki et al., submitted). In this GWAS study,
fourSNPswhichwereallinveryhighLD(r-squared>0.8)in
the 5  region near the PIK3C3 gene were in the top 200SNPs
which showed evidence for association with autoantibody
traits and/or serum IFN-α. Phosphoinositide-3-kinase, class
3 (PIK3C3), is a member of the phosphatidylinositide
3-kinase family that maps to chromosome 18q12. The
PIK3C3 protein, also known as hVps34, plays a role in
vacuolar sorting, and a homolog of this protein in yeast
exhibits similar functions [17]. Recent studies have shown
that PIK3C3 associates with Beclin-1 and is an important
regulator of autophagy [18].
We searched the literature for any previous genetic asso-
ciations between PIK3C3 and human disease and discovered
thatafunctionalvariantinthepromoterregion(rs3813065/-
442 C/T) was associated with susceptibility to schizophrenia
and bipolar disease [19, 20]. Neuropsychiatric manifesta-
tions of SLE are common, ranging from mild cognitive
deﬁcits to seizures and psychosis. These data suggest the
possibility of pathogenic overlap between schizophrenia and
SLE. Also, a previous study demonstrated increased rates
of anti-Sm autoantibodies in both schizophrenic patients
and their healthy relatives, suggesting both heritability and
association of this autoantibody with schizophrenia [21].
This ﬁnding is of particular interest, as the anti-Sm immune
response is thought to be highly speciﬁc for SLE, and like
other SLE-associated autoantibodies anti-Sm is a heritable
trait in SLE families [13]. These data taken together suggest
that some shared heritable elements could contribute to this
particular serologic autoimmunity found in both SLE and
schizophrenia. It was hence interesting to ﬁnd the PIK3C3
locus which has previously been linked to schizophrenia
susceptibility represented in our list of top 200 SNPs in
our GWAS which were associated with SLE serology and
IFN-α levels. The SNPs in PIK3C3 which were found in
our GWAS study were located in the 5  region of the
gene characterized by high LD, and we chose to study the
functional promoter variant of PIK3C3 in an independent
cohort of lupus patients and controls in the present study
to test for association with SLE susceptibility, as well
as potential associations with serology and serum IFN-α
levels.
2. Methods
2.1. Initial GWAS Study Description. The initial cohort of
SLE patients studied in the GWAS scan was obtained from
the Hospital for Special Surgery Lupus Registries, and con-
sistedof104SLEpatients,including20African-American,36
European-American, 32 Hispanic-American, and 16 Asian-
American SLE patients. This study was designed as a case-
case analysis to compare SNP frequencies in SLE patients
with high versus low IFN-α and those with and without
SLE-associated autoantibodies. Patients were selected in
an extremes-of-phenotype design from the top 33% and
bottom 33% of serum IFN-α activity and were additionally
stratiﬁed for the GWAS study by ancestry and the presence
or absence of anti-RBP or anti-dsDNA antibodies. A study
design incorporating multiple ancestral backgrounds was
chosen as both autoantibodies and serum IFN-α levels are
heritable pathogenic factors which are shared between all
ancestral backgrounds. The top 200 SNPs were examined
in detail using expert review of public databases, and the
seven top SNPs chosen for replication all demonstrated
strong associations with either serology or serum IFN-α
in an independent cohort, as would have been expected
based upon the initial GWAS study design (Kariuki et al., in
revision). An SNP 5  to the PIK3C3 gene was also noted as
an SNP of interest among the top 200 SNPs in this GWAS
study. Based upon the data presented in the introduction,
the functional promoter variant 5  of PIK3C3 was chosen for
follow up in this study.
2.2. Validation Cohort. The independent validation cohort
of 478 SLE patients was obtained from the University
of Chicago Translational Research in the Department
of Medicine (TRIDOM) registry and Rush University
Medical Center and consisted of 252 African-American,
152 European-American, and 74 Hispanic-American SLE
patients. All patients met the revised 1982 ACR criteria for
the diagnosis of SLE [22]. Samples from 522 controls were
obtained from the TRIDOM registry, including 361 African-
American and 161 European-American subjects who were
individually screened for the absence of autoimmune disease
by medical record review. The subjects in this study were not
related to each other. Informed consent was obtained from
all subjects at each site, and the study was approved by the
IRB at each institution.
2.3. SNP Genotyping of PIK3C3 rs3813065 in the Validation
Cohort. Individuals in the validation cohort were genotyped
at PIK3C3 rs3813065. Genotyping was performed using
ABI Taqman Assays-by-Design primers and probes on an
ABI 7900HT PCR machine with >98% genotyping success.
Scatter plots were all reviewed individually for quality, and
genotype frequencies did not deviate signiﬁcantly from the
expected Hardy-Weinberg proportions (P>. 01 in all
ancestral backgrounds).
2.4. Reporter Cell Assay for IFN-α. The reporter cell assay
for IFN-α has been described in detail elsewhere [8, 23].
Reporter cells were used to measure the ability of patient
seratocauseIFN-inducedgeneexpression.Thereportercells
(WISH cells, ATCC no. CCL-25) were cultured with 50%
patient sera for 6 hours, and then lysed. mRNA was puriﬁed
from cell lysates, and cDNA was made from total cellular
mRNA. cDNA was then quantiﬁed using real-time PCRJournal of Biomedicine and Biotechnology 3
Table 1: Percent of SLE patients with a positive test for each SLE-
associated autoantibody in each ancestral background.
Ro La Sm RNP DNA Ro and Sm
Af-Am 52 19 38 65 41 24
His 40 10 22 33 48 14
Eur-Am 33 9 13 20 43 4
Af-Am:African-American, His:Hispanic-American, and Eur-Am: Europe-
an-American, Numbers indicate percent of subjects with a positive test in
each category; “Ro and Sm” category indicates subjects with positive tests
for both autoantibodies.
using an Applied Biosystems 7900HT PCR machine with
the SYBR Green ﬂuorophore system. Forward and reverse
primers for the genes MX1, PKR,a n dIFIT1, which are
known to be highly and speciﬁcally induced by IFN-α,w e r e
used in the reaction [8]. GAPDH was ampliﬁed in the same
samples to control for background gene expression.
The amount of PCR product of the IFN-α-induced
gene was normalized to the amount of product for the
housekeeping gene GAPDH in the same sample. The relative
expression of each of the three tested IFN-induced genes
was calculated as a fold increase compared to its expression
in WISH cells cultured with media alone. Results from the
IFN-α assay were standardized to a healthy multiancestral
reference population as previously described, and a serum
IFN-α activity score was calculated based upon the mean
and SD of the reference population [8]. This assay has been
highly informative when applied to SLE as well as other
autoimmune disease populations [8, 24, 25].
2.5. Measurement of Autoantibodies. Antibodies to anti-Ro,
anti-La,anti-Sm,andanti-RNPweremeasuredinallsamples
by ELISA methods using kits from INOVA Diagnostics
(San Diego, CA), and anti-dsDNA antibodies were mea-
sured using Crithidia luciliae immunoﬂuorescence, with
detectable ﬂuorescence considered positive. All samples
were assayed in University of Chicago clinical laboratory
by the same personnel that test clinical samples. For the
ELISA assays, the standard cutoﬀ points for a positive test
designated by the manufacturer were used to categorize
samples as positive or negative. Autoantibody prevalences
in SLE patients of each ancestral background are shown in
Table 1.
2.6. Statistical Analysis. All subjects in the study had geno-
type data available for 13 SNPs, and principal component
analysis was performed on 12 of these 13 SNPs excluding
the PIK3C3 rs3813065 SNP, using the PCA option in
the Cluster program by Eisen et al. [26]. The ﬁrst two
principal components are shown plotted on the X and
Y axes, respectively, in Figure 1, and the ﬁrst component
provides a strong separation of those subjects of self-
reported African-American ancestry from those of self-
reported European-American ancestry. If the zero point
on the X-axis of Figure 1 was used to categorically split
the population, 84.4% of self-reported European ancestry
AA
His
EA
0.05
−0.05
0.05
−0.05
Figure 1: Principal component (PC) analysis including all cases
a n dc o n t r o l s .A .s h o w st h eﬁ r s tP C( x-axis) versus the second PC
(y-axis) for each subject. Each dot represents one subject and is
color-coded by self-reported ancestral background (AA:African-
American, His:Hispanic American, EA:European-American).
subjects fell in the positive range for the ﬁrst principal
component, and 74.3% of self-reported African-American
subjects had a negative value for the ﬁrst principal compo-
nent (P-value for departure from a random distribution of
these two ancestral populations on the X-axis=2.8×10−83).
We included the ﬁrst principal component as a covariate
in all subsequent association analyses to provide control
for diﬀerences in proportional ancestry in both cases and
controls.
Logistic regression models were used to detect associ-
ations between the presence of autoantibodies and geno-
type at rs3813065 using the PLINK program v1.07 [27]
(http://pngu.mgh.harvard.edu/∼purcell/plink/). All logistic
regressions incorporated the ﬁrst principal component as
a covariate to provide some control for genetic ancestry at
the individual level. Testing for homogeneity of odds ratios
obtained in the study was performed using PLINK with the
partitioning of the chi-square test statistic method. The IFN-
α data was nonnormally distributed, and nonparametric
Mann-Whitney U was used to compare quantitative IFN-
α data between two genotype subgroups. When more
than two columns of quantitative data were compared,
the nonparametric one-way ANOVA (Kruskall-Wallis test)
was used to test the hypothesis that the distribution in
at least one column was signiﬁcantly diﬀerent from the
distribution in the other columns. Chi-square test was
used to compare allele frequency data between cases and
controls. P-values shown in the paper are uncorrected for
multiple comparisons. When testing diﬀerences in allele
frequencies between diﬀerent patient groups deﬁned by
autoantibodies, a P-value of .0071 is suﬃcient to control
the family-wise type I error rate at 0.05. For the serum
IFN-α studies in African-American SLE patients, P val-
ues <.0056 would withstand a Bonferroni correction for
the number of comparisons possible between the diﬀer-
ent autoantibody states and genotypes presented on the
graph.4 Journal of Biomedicine and Biotechnology
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Figure 2: Distribution of the number of diﬀerent autoanti-
body speciﬁcities in African-American SLE patients stratiﬁed by
rs3813065 genotype. no. of speciﬁcities=the sum of the number
of positive test results for anti-Ro, anti-La, anti-Sm, anti-RNP, and
anti-dsDNA for a given subject (thus every subject is assigned a
number 0 through 5). The horizontal line in the middle of the
box indicates the median, boundaries of the boxes indicate the
interquartile range, and the error bars show the 10th and 90th
percentile, respectively. The P value for the Kruskall-Wallis test is
shown.
2.7. SCAN Database Query. We searched rs3813065
in the SNP and CNV Annotation (SCAN) database
(http://www.scandb.org/)[ 28]. This database is a searchable
index of genome-wide gene expression data linked to
genome-wide SNP genotype data from the HapMap project.
Gene expression data is derived from studies in which
gene expression arrays were run on Epstein-Barr virus-
transformed lymphoblastoid cell lines from individuals
genotyped in the HapMap project. The SCAN database
contains expression data from both European (Centre
d’Etude du Polymorphisme Humain or CEPH) and West
African (Yoruba or YRI) HapMap reference populations. We
searched the database using rs3813065 as the query term,
with a threshold P value of 10
−4.
3. Results
3.1. Association of rs3813065 with Autoantibody Speciﬁcities.
We detected an association between the C allele of rs3813065
and increasing number of autoantibody speciﬁcities in
African-American SLE patients (P = .0057, Figure 2).
The number of antibody speciﬁcities was calculated as the
sum of the number of positive results for anti-Ro, anti-La,
anti-Sm, anti-RNP, and anti-dsDNA antibody testing in a
given SLE patient, for a maximum of 5 distinct antibody
speciﬁcities.ThisP valueof .0057wouldexceedaBonferroni
correction for the number of speciﬁcities analyzed. There
were similar nonsigniﬁcant trends in the Hispanic-American
and European-American cohorts (P=.23 and.32, resp., data
not shown).
3.2. Association of rs3813065 with Individual Autoantibodies.
Logistic regression models were run to detect associations
between rs3813065 C and each SLE-associated autoantibody
individually and follow up models assessed associations
with autoantibody combinations. Both anti-Ro and anti-
Sm showed evidence for association with rs3813065 C
allele in African-Americans, and the best ﬁt model was
achieved between the rs3813065 C and the combination
of anti-Ro and anti-Sm antibodies in this background
(Table 1,OR=2.24,95%CI=1.34–3.73, andP=2.0×10−3).
This association clearly withstands Bonferroni correction
for the number of comparisons in this study. A similar
nonsigniﬁcanttrendwasobservedforanassociationbetween
rs3813065 C and the combination of anti-Ro and anti-Sm
antibodies in Hispanic-American and European-American
subjects (OR=3.30, P=.14 and OR=2.22, P=.45, resp.,
Table 2). While the direction and magnitude of the odds
ratio for association was similar in each background,
independent statistical signiﬁcance was not observed in
the Hispanic- and European-American subjects due to the
low prevalence of the anti-Ro/anti-Sm serologic proﬁle
(Table 1). The odds ratios for association of the rs3813065
C allele with the anti-Ro/anti-Sm antibody proﬁle in
each individual ancestral background were not signiﬁcantly
diﬀerent (χ2 =0.21, P=.90). A meta-analysis across all
three ancestral backgrounds supported a signiﬁcant overall
association (OR=2.26, 95% CI=1.43–3.55, and P=5.0 ×
10−4) although most of data supporting this meta-analysis
association is derived from the African-American subjects in
whom this antibody proﬁle is the most prevalent.
3.3. Association of rs3813065 with Serum IFN-α Activity in
African-Americans. Genetic variation at the rs3813065 SNP
was not associated independently with diﬀerences in serum
IFN-α, however the African-American SLE patients who had
both anti-Ro and anti-Sm had higher serum IFN-α than
thoseSLEpatientswholackedthisantibodyproﬁle(Figure 3,
P =7.6×10−6). These data support a secondary association
with serum IFN-α, in which genetic variation is associated
with the anti-Ro/anti-Sm antibody proﬁle, and then the
particularserologicproﬁleisassociatedwithincreasedserum
IFN-α.
3.4. Case-Control Association Study of PIK3C3 rs3813065.
There were no signiﬁcant diﬀerences in allele frequencies
between cases and controls in our cohort although the C
allele trended toward enrichment in the African-American
cases as compared to controls (Table 3,O R=1.07, P =.63).
rs3813065 C allele frequency in African-American cases
lacking either anti-Ro or anti-Sm antibodies was similar
to African-American controls (0.605 versus 0.620, resp.),
supporting the idea that the C allele is speciﬁcally enriched
with the subgroup of patients who have both anti-Ro and
anti-Sm antibodies.Journal of Biomedicine and Biotechnology 5
Table 2: Association of the rs3813065 C allele with anti-Ro and anti-Sm positive patients in each ancestral background.
Antibody proﬁle MAF OR (C allele) 95 CI P value
African-american Ro+ Sm+ SLE 0.245 2.24 1.34–3.73 2.0×10−3
All other SLE 0.395
Hispanic-american Ro+ Sm+ SLE 0.119 3.30 0.67–16.25 .14
All other SLE 0.248
European-american Ro+ Sm+ SLE 0.115 2.21 0.28–17.67 .45
All other SLE 0.160
Meta-analysis Ro+ Sm+ SLE versus
all other SLE — 2.26 1.43–3.55 5.0×10−4
MAF:minor allele frequency, OR:odds ratio for association of the C allele with Ro+Sm+ patients as compared to all other SLE patients, and 95 CI=95%
conﬁdence interval of the odds ratio.
Table 3:Case-controlassociationofrs3813065withSLEinAfrican-
and European-American subjects.
MAF OR (C allele) 95 CI P value
AA cases 0.320 1.07 0.82–1.38 .63
AA controls 0.380
EA cases 0.155 0.65 0.40–1.06 .09
EA controls 0.115
MAF:minor allele frequency, OR:odds ratio for association of the C allele
in SLE cases as compared to controls in each ancestral background, and 95
CI=95% conﬁdence interval of the odds ratio.
3.5. Association of PIK3C3 rs3813065 with ERAP2 Expres-
sion in the SCAN Database. We next queried the SCAN
database (http://www.scandb.org/) to determine whether
genetic variation at the rs3813065 SNP was associated with
any signiﬁcant diﬀerences in global gene expression in EBV-
transformedlymphoblastoidcelllinesderivedfromHapMap
individuals [28]. Interestingly, the rs3813065 SNP was asso-
ciated with a highly signiﬁcant diﬀerence in the expression
of endoplasmic reticulum aminopeptidase 2 (ERAP2)i n
the HapMap cell lines derived from the African Yoruba
population (P=2×10−5). The ERAP2 gene is located on
chromosome5q15andthemolecularmechanismunderlying
this association is not known. ERAP2 is expressed in the
endoplasmic reticulum, and is involved in precursor peptide
processing prior to binding to HLA class I molecules in
the endoplasmic reticulum [29]. No other transcript levels
were associated with rs3813065, including PIK3C3 itself,
in the Yoruba population. There were no associations
between variation at rs3813065 and gene expression levels
in lymphoblastoid cells from the representative European-
derived CEPH HapMap population.
4. Discussion
We ﬁnd that genetic variation in the promoter region of the
PIK3C3 gene is associated with a very particular serologic
phenotypeinAfrican-AmericanSLEpatients.Itisinteresting
that we ﬁnd a primary association with serology and not
with serum IFN-α levels, although autoantibodies may be
more highly heritable than IFN-α. In SLE families, anti-Ro
P = 7.6 ×10−6
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Figure 3: Serum IFN-α activity in African-American SLE patients
stratiﬁed by rs3813065 genotype and presence or absence of the
anti-Ro positive/anti-Sm positive serologic phenotype. Serum IFN-
α is represented in relative units on the Y-axis, as described in
Methods. “Anti-Ro+/Anti-Sm+” indicates SLE patients who have
positive tests for both anti-Ro and anti-Sm, and “All others”
indicates all of the other SLE patients who lack one or both of
these autoantibodies. Line drawn at the median and error bars
show the interquartile range. P value by Mann-Whitney U test for a
diﬀerence between subjects with CT genotype with versus without
the anti-Ro+/anti-Sm+ serology.
antibodies are characterized by a relative recurrence risk of
9.7 [13] while high IFN-α has a relative recurrence risk of
3.8 [8]. Relative recurrence risk for anti-Sm in SLE families
is incalculable in the same large study [13], as none of the
877controlshadapositiveresultforanti-Sm.However,0.2%
of the 819 unaﬀected relatives of SLE patients had a positive
anti-Smtest,supportingprobablefamilialaggregationofthis
autoantibody trait as well.
The rs3813065 SNP has been associated with schizophre-
nia in multiple ancestral backgrounds [19, 20]. In the
largest study to date in Chinese individuals, the rs3813065
C allele was associated with increased risk of schizophrenia
(OR=1.24, P=.017) [20], and a Chinese family-based6 Journal of Biomedicine and Biotechnology
association study demonstrated similar ﬁndings (OR=1.51,
P=.0036 for association of the C allele) [30]. A study exam-
ining the rs3813065 allele in European ancestry populations
did not ﬁnd evidence for an association with schizophrenia
while there was some evidence for association between
the opposite allele (T allele) with risk of schizophrenia
in a Jewish population [19]. Thus, while published data
supportanassociation betweenthis locusandschizophrenia,
there appears to be signiﬁcant heterogeneity of association
between diﬀerent world populations. SNPs in or near the
PIK3C3 locus have not been associated with SLE in genome-
widestudiestodate;howeverthesestudieshaveonlyassessed
European ancestry individuals and have not stratiﬁed by
subphenotypes such as autoantibody traits.
Studies have implicated polygenic and environmental
causes for both SLE [31] and schizophrenia [32, 33]. Infec-
tion with the Epstein-Barr virus (EBV) has been strongly
implicated as an environmental risk factor for SLE [34], and
the herpes virus family may play a role in the development
of schizophrenia [35, 36]. Studies suggest that formation
of the characteristic SLE-associated autoantibodies anti-Sm
and anti-Ro can be triggered by antigenic cross-reactivity
with anti-Epstein-Barr virus nuclear antigen-1 (EBNA-1)
antibodies [31, 37]. Work in mice and rabbits demonstrated
that immunization with EBNA-1 peptides can elicit the
production of anti-Sm and anti-RNP autoantibodies [38].
Interestingly, in our study the C allele of the rs3813065 SNP
was strongly associated with anti-Ro combined with anti-Sm
antibodies in African-American SLE patients. Studies have
shown that anti-Sm antibodies are also elevated in patients
with schizophrenia and their healthy family members [21];
however it is not known whether this polymorphism is
associatedwithanti-Smantibodiesinschizophreniapatients.
The strong association between the rs3813065 SNP
and ERAP2 expression is of particular interest. ERAP2 is
expressed in the endoplasmic reticulum and is involved in
the processing of precursor peptides prior to their binding
to HLA class I molecules in the endoplasmic reticulum [29].
HLA class I molecules present cytosolic peptides, including
peptides derived from viruses, allowing presentation of
antigens to the adaptive immune system and subsequent
development of an immune response directed against the
particular peptide. It is possible that dysregulation in
ERAP2 expression due to variation in the PIK3C3 gene
could lead to alternate peptide processing and presentation
on MHC molecules. Improper peptide processing could
enhancethechancesofanti-self-immuneresponse.Thus,the
association of rs3813065 C with the formation of particular
autoantibodies in SLE patients could be related to alternate
ERAP2-mediated peptide processing prior to presentation
on MHC molecules. This could begin to explain the curious
ﬁnding of anti-Sm antibodies in schizophrenia patients
and their family members although the data presented
in this paper are only statistically signiﬁcant in African-
Americans, and the PIK3C3 SNP has not been deﬁnitively
associated with schizophrenia in African-Americans [39].
Studies examining whether this polymorphism is related
to anti-Sm serology in schizophrenia patients, and studies
to determine whether there is any association between this
variant and neuropsychiatric manifestations of SLE will be
important areas for future work.
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